Australia markets closed

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.67000.0000 (0.00%)
As of 03:19PM EDT. Market open.

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 294

Key executives

NameTitlePayExercisedYear born
Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director879.06kN/A1965
Dr. David J. D. Sourdive Ph.D.Director, Deputy CEO, Exec. VP of CMC and Manufacturing580.28kN/A1967
Dr. Bing C. Wang M.B.A., Ph.D.Chief Financial OfficerN/AN/A1977
Valerie CrosPrincipal Financial Officer & Principal Accounting OfficerN/AN/AN/A
Mr. Jean Charles EpinatChief Technological OfficerN/AN/AN/A
Dr. Philippe Duchateau Ph.D.Chief Scientific OfficerN/AN/A1963
Mr. Stephan Reynier M.Sc., MScChief Regulatory & Pharmaceutical Compliance OfficerN/AN/A1969
Ms. Marie-Bleuenn TerrierGen. Counsel & Sec. of the Board of DirectorsN/AN/A1982
Pascalyne WilsonDirector of CommunicationsN/AN/AN/A
Ms. Kyung Nam-WortmanExec. VP & Chief HR OfficerN/AN/A1970
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Corporate governance

Cellectis S.A.’s ISS governance QualityScore as of 31 July 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.